Halozyme Therapeutics Inc (HALO) concluded trading on Thursday at a closing price of $53.96, with 3.21 million shares of worth about $173.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 18.88% during that period and on November 14, 2024 the price saw a loss of about -7.93%. Currently the company’s common shares owned by public are about 126.77M shares, out of which, 125.85M shares are available for trading.
Stock saw a price change of -9.54% in past 5 days and over the past one month there was a price change of 0.94%. Year-to-date (YTD), HALO shares are showing a performance of 46.00% which increased to 33.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $33.15 but also hit the highest price of $65.53 during that period. The average intraday trading volume for Halozyme Therapeutics Inc shares is 1.38 million. The stock is currently trading -1.57% below its 20-day simple moving average (SMA20), while that difference is down -4.18% for SMA50 and it goes to 10.21% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Halozyme Therapeutics Inc (NASDAQ: HALO) currently have 126.77M outstanding shares and institutions hold larger chunk of about 98.42% of that.
The stock has a current market capitalization of $6.87B and its 3Y-monthly beta is at 1.28. PE ratio of stock for trailing 12 months is 17.86, while it has posted earnings per share of $3.02 in the same period. Its PEG reads 0.62 and has Quick Ratio of 9.15 while making debt-to-equity ratio of 3.32. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HALO, volatility over the week remained 5.02% while standing at 3.66% over the month.
Stock’s fiscal year EPS is expected to rise by 42.35% while it is estimated to increase by 16.55% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on October 07, 2024 offering an Equal weight rating for the stock and assigned a target price range of between $58 and $62 to it. Coverage by JP Morgan stated Halozyme Therapeutics Inc (HALO) stock as a Neutral in their note to investors on September 19, 2024, suggesting a price target of $57 for the stock. On June 07, 2024, Piper Sandler Downgrade their recommendations, while on February 29, 2024, TD Cowen Initiated their ratings for the stock with a price target of $54. Stock get a Buy rating from H.C. Wainwright on July 24, 2023.
